NCT05006794: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Chemotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on at least 1 prior standard therapeutic regimen; Patients with triple negative breast cancer (TNBC) are eligible for the dose expansion phase
Exclusions: Patients with unstable untreated symptomatic brain metastases – see trial for details; Patients with a history of leptomeningeal disease; Patients with prior treatment of any myeloid cell leukemia 1 (MCL1) inhibitor; For dose expansion phase, TNBC patients with more than 1 prior chemotherapy regimen

Comments are closed.

Up ↑